Andrew Hudson

Andrew is Global Head of Pharmacovigilance (PV) & Scientific Development within Product Development Safety & Risk Management at Hoffmann-La Roche Ltd, and is based in the UK. Andrew joined Roche in 2014 and leads a global function that coordinates the overall patient safety strategy at Roche, and enables PV, clinical risk management, safety science, digital safety & safety systems, operations, and safety process and policy activities.

Prior to joining Roche, Andrew held leadership positions in clinical safety and product development with AstraZeneca and GSK, where he started his healthcare industry career. In addition to his involvement with TransCelerate, where he has been a member of the PV Leadership team and co-sponsor of the Intelligent Automation in PV program since 2017, Andrew is also a member of the Advisory Committee for the PV Programme at The University of Hertfordshire. Additionally, he is an advisor on the EMA’s Eudravigilance Expert Working Group and has previously participated in several EU Innovative Medicines Initiatives.

Andrew originally trained and worked as a clinical pharmacist, prior to completing his Ph.D. at Aston University. He has also gained post-graduate qualifications in PV and Pharmacoepidemiology (London School of Hygiene & Tropical Medicine) and a Masters in Business Administration (MBA) from The University of Manchester Business School.